EU Panel Backs AstraZeneca’s Baxdrostat for Marketing Authorisation
AstraZeneca said a European medicines committee backed its hypertension pill, branded Baxfendy, for marketing authorisation. If authorised, it could be the first drug of its class available to patients in the EU.
AstraZeneca LSE:AZN said on Friday a European medicines committee had backed its hypertension pill baxdrostat, branded as Baxfendy, for marketing authorisation, potentially making it the first drug of its class to reach patients in the European Union.